Study Sees Satralizumab Benefits for TED Over 48 Weeks
Summary
Data from a pair of clinical trials show durable improvements in symptoms with the IL-6 receptor inhibitor, but questions over its cost-effectiveness cloud findings.
Description from Medscape.
Who is covering this
-
Study Sees Satralizumab Benefits for TED Over 48 Weeks
Data from a pair of clinical trials show durable improvements in symptoms with the IL-6 receptor inhibitor, but questions over its cost-effectiveness cloud findings.
Comments
Comments need JavaScript.